Expression of p16 and p53 in non-small-cell lung cancer: clinicopathological correlation and potential prognostic impact.

<b>Aim:</b> p16 and p53 are frequently altered intracellular pathways in cancers. We investigated the aberrant expression of p16 and its relationship with p53 and HPV status in primary non-small-cell lung carcinoma. <b>Patients & methods:</b> Lung tumor tissue microarray (n = 163), immunohistochemical study of p16 and p53, and HPV <i>in-situ</i> hybridization were analyzed. <b>Results:</b> p16 and p53 were detected in 50.7 and 57.3% of adenocarcinoma (ADCs; n = 75), and 35.2 and 63.6% of squamous cell carcinoma (n = 88). HPV was detected in 16 and 10.2% of ADC and squamous cell carcinoma. In ADCs, p16 positive tumors demonstrated a favorable median overall survival time of 60.9 months, compared with p16 negative tumors of 46.9 months (p < 0.05). Furthermore, we did not find significant relationships between p16 expression and HPV status, nor with p53 expression. <b>Conclusion:</b> p16 play an unique role in lung cancer survival. The mechanism of p16 needs to be further studied.

Ao M, Askin F, Gabrielson E, Höti N, Li L, Li QK, Zhang H, Zhang Z, Zhou Y, Zhu H

31157548

Biomark Med, 2019, 13 (9)

Version 5.1.0